

April 21, 2020  
 Symbio Pharmaceuticals Limited  
 Fuminori Yoshida  
 Representative Director,  
 President and Chief Executive Officer

**Notice of the Large Volume Exercise of the 50<sup>th</sup> Stock Acquisition Rights (with Exercise Price Revision Clauses)  
 Issued by way of Third Party Allotment**

TOKYO, Japan, April 21, 2020—Symbio Pharmaceuticals Limited announces the large volume exercise of the 50<sup>th</sup> Stock Acquisition Rights, issued and allotted to EVO FUND on March 16, 2020, during the period from April 15, 2020 to April 21, 2020, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 50 <sup>th</sup> Stock Acquisition Rights
(2)	Number of issued shares from the previous disclosure	700,000 Shares
(3)	Number of stock acquisition rights being exercised from the previous disclosure and the ratio to the entire issue	700,000 Units (Ratio to the total number of stock acquisition rights issued 7,000,000 units : 10.0%)
(4)	Number of unexercised stock acquisition rights as of the previous disclosure	5,500,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	4,800,000 Units

(6) Exercise status from the previous disclosure

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
April 15 (Wed)	-	-	303	-
April 16 (Thu)	-	-	303	-
April 17 (Fri)	-	-	303	-
April 20 (Mon)	-	-	303	-
April 21 (Tue)	700,000	-	303	700,000

※Number of issued shares at the end of the previous month : 28,465,381 shares [of which 21,593 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 50<sup>th</sup> and 51<sup>st</sup> Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)” published on February 27, 2020.